Patients with tuberculosis can now complete treatment in a shorter, fully oral course, reducing side effects and improving adherence. The new regimens replace traditional 6-month therapies with shorter course. The shorter treatments could ease patient burdens, lower costs, and increase cure rates, but their real-world impact in high-burden countries such as India has yet to be fully assessed.